CN103068389A - 1-[2-(2,4-二甲基-苯硫基)苯基]哌嗪的治疗用途 - Google Patents

1-[2-(2,4-二甲基-苯硫基)苯基]哌嗪的治疗用途 Download PDF

Info

Publication number
CN103068389A
CN103068389A CN2011800406861A CN201180040686A CN103068389A CN 103068389 A CN103068389 A CN 103068389A CN 2011800406861 A CN2011800406861 A CN 2011800406861A CN 201180040686 A CN201180040686 A CN 201180040686A CN 103068389 A CN103068389 A CN 103068389A
Authority
CN
China
Prior art keywords
patient
dimethyl
phenyl
piperazine
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2011800406861A
Other languages
English (en)
Chinese (zh)
Inventor
M.德拉海姆
I.弗洛雷亚
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
H Lundbeck AS
Original Assignee
H Lundbeck AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44532506&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN103068389(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by H Lundbeck AS filed Critical H Lundbeck AS
Publication of CN103068389A publication Critical patent/CN103068389A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN2011800406861A 2010-08-23 2011-08-22 1-[2-(2,4-二甲基-苯硫基)苯基]哌嗪的治疗用途 Pending CN103068389A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA201000739 2010-08-23
DKPA201000739 2010-08-23
PCT/DK2011/050317 WO2012025123A1 (en) 2010-08-23 2011-08-22 Therapeutic uses of 1-[2-(2,4-dimethyl-phenylsulfanyl)phenyl]piperazine

Publications (1)

Publication Number Publication Date
CN103068389A true CN103068389A (zh) 2013-04-24

Family

ID=44532506

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2011800406861A Pending CN103068389A (zh) 2010-08-23 2011-08-22 1-[2-(2,4-二甲基-苯硫基)苯基]哌嗪的治疗用途

Country Status (32)

Country Link
US (5) US20130184291A1 (https=)
EP (1) EP2608789B2 (https=)
JP (1) JP5902169B2 (https=)
KR (1) KR101816953B1 (https=)
CN (1) CN103068389A (https=)
AP (1) AP3583A (https=)
AR (1) AR082501A1 (https=)
AU (1) AU2011295465B8 (https=)
BR (2) BR122020025600A2 (https=)
CA (1) CA2807062C (https=)
CL (1) CL2013000492A1 (https=)
CO (1) CO6680652A2 (https=)
CY (1) CY1118886T1 (https=)
DK (1) DK2608789T4 (https=)
ES (1) ES2625142T5 (https=)
FI (1) FI2608789T4 (https=)
HR (1) HRP20170608T4 (https=)
HU (1) HUE034155T2 (https=)
IL (1) IL224371A (https=)
LT (1) LT2608789T (https=)
ME (1) ME02674B (https=)
MX (1) MX349724B (https=)
PL (1) PL2608789T5 (https=)
PT (1) PT2608789T (https=)
RS (1) RS55851B2 (https=)
RU (1) RU2564666C2 (https=)
SG (1) SG187649A1 (https=)
SI (1) SI2608789T2 (https=)
SM (1) SMT201700239T1 (https=)
TW (1) TW201212918A (https=)
WO (1) WO2012025123A1 (https=)
ZA (1) ZA201301385B (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104119299A (zh) * 2014-08-13 2014-10-29 北京蓝贝望生物医药科技股份有限公司 沃赛汀或沃替西汀的氢溴酸盐
CN104119298A (zh) * 2014-08-13 2014-10-29 北京蓝贝望生物医药科技股份有限公司 氢溴酸沃赛汀或氢溴酸沃替西汀
CN104610195A (zh) * 2015-01-30 2015-05-13 上虞京新药业有限公司 沃替西汀的天冬氨酸盐或其水合物及其制备方法和用途

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106103418A (zh) 2014-01-31 2016-11-09 埃吉斯药物私人有限公司 沃替西汀盐的制备方法
WO2018002115A1 (en) 2016-07-01 2018-01-04 H. Lundbeck A/S Vortioxetine dosing regimes for fast onset of antidepressant effect
US20210393621A1 (en) 2018-10-26 2021-12-23 The Research Foundation For The State University Of New York Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007144005A1 (en) * 2006-06-16 2007-12-21 H. Lundbeck A/S 1- [2- (2, 4-dimethylphenylsulfanyl) -phenyl] piperazine as a compound with combined serotonin reuptake, 5-ht3 and 5-ht1a activity for the treatment of cognitive impairment
WO2009062517A1 (en) * 2007-11-13 2009-05-22 H. Lundbeck A/S Therapeutic uses of compounds having combined sert, 5-ht3 and 5-ht1a activity

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8430581D0 (en) * 1984-12-04 1985-01-09 Ferrosan As Treatment
DK0543584T3 (da) * 1991-11-18 1996-07-01 Lilly Industries Ltd Benzo(b)thiophen-2-carboxamider til behandling af forstyrrelser i centralnervesystemet
US20080103179A1 (en) * 2006-10-27 2008-05-01 Tam Peter Y Combination Therapy
EP2090769A1 (en) 2000-10-02 2009-08-19 Rohr, Inc. Apparatus, method and system for gas turbine engine noise reduction
UA81749C2 (uk) * 2001-10-04 2008-02-11 Х. Луннбек А/С Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну
TW200848411A (en) 2007-03-20 2008-12-16 Lundbeck & Co As H Novel therapeutic uses of 1-[2-(2, 4-dimethylphenylsulfanyl)phenyl]-piperazine

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007144005A1 (en) * 2006-06-16 2007-12-21 H. Lundbeck A/S 1- [2- (2, 4-dimethylphenylsulfanyl) -phenyl] piperazine as a compound with combined serotonin reuptake, 5-ht3 and 5-ht1a activity for the treatment of cognitive impairment
WO2009062517A1 (en) * 2007-11-13 2009-05-22 H. Lundbeck A/S Therapeutic uses of compounds having combined sert, 5-ht3 and 5-ht1a activity

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ARTIGAS F 等.: "A randomised, double-blind, placebo-controlled, active-referenced study of Lu AA21004 in patients with major depression.", 《EUROPEAN NEUROPSYCHOPHARMACOLOGY》, vol. 19, 1 September 2009 (2009-09-01), XP026717401, DOI: doi:10.1016/S0924-977X(09)70661-3 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104119299A (zh) * 2014-08-13 2014-10-29 北京蓝贝望生物医药科技股份有限公司 沃赛汀或沃替西汀的氢溴酸盐
CN104119298A (zh) * 2014-08-13 2014-10-29 北京蓝贝望生物医药科技股份有限公司 氢溴酸沃赛汀或氢溴酸沃替西汀
CN104119299B (zh) * 2014-08-13 2016-08-17 北京蓝贝望生物医药科技股份有限公司 沃赛汀或沃替西汀的氢溴酸盐
CN104119298B (zh) * 2014-08-13 2016-08-24 北京蓝贝望生物医药科技股份有限公司 氢溴酸沃赛汀或氢溴酸沃替西汀
CN104610195A (zh) * 2015-01-30 2015-05-13 上虞京新药业有限公司 沃替西汀的天冬氨酸盐或其水合物及其制备方法和用途

Also Published As

Publication number Publication date
AR082501A1 (es) 2012-12-12
CO6680652A2 (es) 2013-05-31
HRP20170608T4 (hr) 2024-12-06
WO2012025123A1 (en) 2012-03-01
CA2807062C (en) 2018-07-31
SG187649A1 (en) 2013-03-28
IL224371A (en) 2016-07-31
ME02674B (me) 2017-06-20
US20240293397A1 (en) 2024-09-05
EP2608789A1 (en) 2013-07-03
AU2011295465B2 (en) 2014-06-19
LT2608789T (lt) 2017-05-25
AU2011295465B8 (en) 2014-07-10
EP2608789B2 (en) 2024-08-21
BR112013002194A2 (pt) 2016-05-31
ES2625142T5 (en) 2025-02-10
US20130184291A1 (en) 2013-07-18
HUE034155T2 (en) 2018-01-29
MX349724B (es) 2017-08-10
CA2807062A1 (en) 2012-03-01
PL2608789T5 (pl) 2025-11-12
RS55851B2 (sr) 2024-11-29
JP2013536206A (ja) 2013-09-19
RU2564666C2 (ru) 2015-10-10
SI2608789T2 (sl) 2025-05-30
SI2608789T1 (sl) 2017-06-30
PL2608789T3 (pl) 2017-09-29
AP3583A (en) 2016-02-09
TW201212918A (en) 2012-04-01
ES2625142T3 (es) 2017-07-18
BR122020025600A2 (pt) 2021-01-05
PT2608789T (pt) 2017-05-26
CY1118886T1 (el) 2018-01-10
DK2608789T4 (da) 2024-11-04
JP5902169B2 (ja) 2016-04-13
EP2608789B1 (en) 2017-04-12
HRP20170608T1 (hr) 2017-07-28
AP2013006768A0 (en) 2012-03-31
US20190000836A1 (en) 2019-01-03
DK2608789T3 (en) 2017-05-15
KR101816953B1 (ko) 2018-01-09
US20210085674A1 (en) 2021-03-25
SMT201700239T1 (it) 2017-07-18
RU2013112890A (ru) 2014-09-27
MX2013001570A (es) 2013-03-21
US20220370439A1 (en) 2022-11-24
FI2608789T4 (fi) 2024-11-01
RS55851B1 (sr) 2017-08-31
CL2013000492A1 (es) 2013-06-07
AU2011295465A1 (en) 2013-02-07
KR20130097162A (ko) 2013-09-02
ZA201301385B (en) 2014-04-30

Similar Documents

Publication Publication Date Title
US20240293397A1 (en) Therapeutic uses of 1-[2-(2,4-dimethyl-phenylsulfanyl)phenyl]piperazine
AU2021229240B2 (en) Compositions comprising 2-((1-(2(4-Fluorophenyl)-2-oxoethyl)piperidin-4-yl)methyl)isoindolin-1-one for treating schizophrenia
Outfitters et al. Revisiting monoamine oxidase inhibitors
Bellingham et al. Duloxetine: a review of its pharmacology and use in chronic pain management
AU2008266906A1 (en) Combination therapy for depression
US20090068290A1 (en) Bifeprunox doses for treating schizophrenia
SK17512000A3 (sk) Liek na liečenie nepoddajnej depresie a farmaceutická kompozícia
DE69607904T2 (de) Potenzierung von Serotonin-Wirkstoffresponz
JPWO2011013639A1 (ja) 錠剤
Love et al. Long-acting risperidone injection
US6008222A (en) Method for oral administration of buspirone and nefazodone
Uchida et al. Medications for psychosis: dopamine blockers and dopamine partial agonists (antipsychotics)
HK1184374A (en) Therapeutic uses of 1-[2-(2,4-dimethyl-phenylsulfanyl)phenyl]piperazine
US20240238260A1 (en) Noradrenergic and specific serotonergic anxiolytic and antidepressant, method for the production and use thereof
JPWO2013129436A1 (ja) 経口剤

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1184374

Country of ref document: HK

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20130424

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1184374

Country of ref document: HK